These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 38833252)

  • 1. Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer.
    Iyer HS; Stone BV; Roscoe C; Hsieh MC; Stroup AM; Wiggins CL; Schumacher FR; Gomez SL; Rebbeck TR; Trinh QD
    JAMA Netw Open; 2024 Jun; 7(6):e2414582. PubMed ID: 38833252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic Distribution of Racial Differences in Prostate Cancer Mortality.
    Fletcher SA; Marchese M; Cole AP; Mahal BA; Friedlander DF; Krimphove M; Kilbridge KL; Lipsitz SR; Nguyen PL; Choueiri TK; Kibel AS; Trinh QD
    JAMA Netw Open; 2020 Mar; 3(3):e201839. PubMed ID: 32232449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association of County-level Prostate-specific Antigen Screening with Metastatic Prostate Cancer and Prostate Cancer Mortality.
    Stone BV; Labban M; Beatrici E; Filipas DK; D'Amico AV; Lipsitz SR; Choueiri TK; Kibel AS; Cole AP; Iyer HS; Trinh QD
    Eur Urol Oncol; 2024 Jun; 7(3):563-569. PubMed ID: 38155059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans.
    Sherer MV; Qiao EM; Kotha NV; Qian AS; Rose BS
    JAMA Oncol; 2022 Oct; 8(10):1471-1476. PubMed ID: 35925581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
    Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
    JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variations in Age-Adjusted Prostate Cancer Incidence Rates by Race and Ethnicity After Changes in Prostate-Specific Antigen Screening Recommendation.
    Lai SM; Keighley J; Garimella S; Enko M; Parker WP
    JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
    Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
    JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
    Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
    JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care Systems.
    Wadhwa A; Roscoe C; Duran EA; Kwan L; Haroldsen CL; Shelton JB; Cullen J; Knudsen BS; Rettig MB; Pyarajan S; Nickols NG; Maxwell KN; Yamoah K; Rose BS; Rebbeck TR; Iyer HS; Garraway IP
    JAMA Netw Open; 2024 Mar; 7(3):e242852. PubMed ID: 38502125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
    Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
    JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
    Dall'Era MA; deVere-White R; Rodriguez D; Cress R
    Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
    Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
    Ann Oncol; 2017 May; 28(5):1098-1104. PubMed ID: 28453693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
    Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
    JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
    Martin RM; Donovan JL; Turner EL; Metcalfe C; Young GJ; Walsh EI; Lane JA; Noble S; Oliver SE; Evans S; Sterne JAC; Holding P; Ben-Shlomo Y; Brindle P; Williams NJ; Hill EM; Ng SY; Toole J; Tazewell MK; Hughes LJ; Davies CF; Thorn JC; Down E; Davey Smith G; Neal DE; Hamdy FC;
    JAMA; 2018 Mar; 319(9):883-895. PubMed ID: 29509864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program.
    Morley F; Iyer HS; Tamimi RM; Nanus DM; Rebbeck TR; Kensler KH
    Cancer Causes Control; 2024 Mar; 35(3):509-521. PubMed ID: 37878135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Value Prostate-Specific Antigen Screening in Older Males.
    Kalavacherla S; Riviere P; Javier-DesLoges J; Banegas MP; McKay RR; Murphy JD; Rose BS
    JAMA Netw Open; 2023 Apr; 6(4):e237504. PubMed ID: 37040113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
    Washington SL; Jeong CW; Lonergan PE; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
    JAMA Netw Open; 2020 Dec; 3(12):e2031349. PubMed ID: 33369661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation.
    Kensler KH; Pernar CH; Mahal BA; Nguyen PL; Trinh QD; Kibel AS; Rebbeck TR
    J Natl Cancer Inst; 2021 Jun; 113(6):719-726. PubMed ID: 33146392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.